Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols

International Journal of Endocrinology

Volumn 2016, Issue , 2016, Pages

  Laganà, Antonio Simone ^a   Rossetti, Paola ^b   Buscema, Massimo ^b   La Vignera, Sandro ^c   Condorelli, Rosita Angela ^c   Gullo, Giuseppe ^a   Granese, Roberta ^a   Triolo, Onofrio ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b CANNIZZARO HOSPITAL   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO CHIRO INOSITOL; FOLIC ACID; INOSITOL; INSULIN SENSITIZING AGENT; METFORMIN; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; UNCLASSIFIED DRUG;

ANOVULATION; CONSENSUS DEVELOPMENT; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; IN VITRO FERTILIZATION; INSULIN RESISTANCE; MENSTRUAL IRREGULARITY; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVARY FOLLICLE MATURATION; OVARY FUNCTION; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK REDUCTION; SECOND MESSENGER; SIGNAL TRANSDUCTION;

EID: 84984977913     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2016/6306410     Document Type: Review

References (71)

1. S. Franks, "Polycystic ovarian syndrome, " The New England Journal of Medicine, vol. 333, no. 13, pp. 853-861, 1995.
2. W. A. March, V. M. Moore, K. J. Willson, D. I.W. Phillips, R. J. Norman, and M. J. Davies, "The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria, " Human Reproduction, vol. 25, no. 2, pp. 544-551, 2010.
3. RotterdamESHRE/ASRM-Sponsored PCOS ConsensusWorkshop Group, "Revised 2003 consensus on diagnostic criteria and long-Term health risks related to polycystic ovary syndrome (PCOS), " Human Reproduction, vol. 19, no. 1, pp. 41-74, 2004.
4. J. K. Zawadzki and A.Dunaif, "Diagnostic criteria for polycystic ovary syndrome: Towards a rationale approach, " in The Polycystic Ovarian Syndrome, A. Dunaif, J. R. Givens, F. Haseltine, and G. R. Merriam, Eds., pp. 377-384, Blackwell Scientific Publication, Boston, Mass, USA, 1992.
5. R. Azziz, E. Carmina, D. Dewailly et al., "The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report, " Fertility and Sterility, vol. 91, no. 2, pp. 456-488, 2009.
6. The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS ConsensusWorkshop Group, "Consensus on womens health aspects of polycystic ovary syndrome (PCOS), " Human Reproduction, vol. 27, no. 1, pp. 14-24, 2012.
7. D. Apter, "Endocrine and metabolic abnormalities in adolescents with a PCOS-like condition: consequences for adult reproduction, " Trends in Endocrinology and Metabolism, vol. 9, no. 2, pp. 58-61, 1998.
8. S. Venturoli, E. Porcu, R. Fabbri et al., "Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence, " Pediatric Research, vol. 38, no. 6, pp. 974-980, 1995.
9. M. Mortensen, R. L. Rosenfield, and E. Littlejohn, "Functional significance of polycystic-size ovaries in healthy adolescents, " Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 3786-3790, 2006.
10. S. K. Blank, K. D. Helm, C. R. McCartney, and J. C. Marshall, "Polycystic ovary syndrome in adolescence, " Annals of the New York Academy of Sciences, vol. 1135, pp. 76-84, 2008.
11. E. Carmina, S. E. Oberfield, and R. A. Lobo, "The diagnosis of polycystic ovary syndrome in adolescents, " American Journal of Obstetrics and Gynecology, vol. 203, no. 3, pp. 201.e1-201.e5, 2010.
12. G. A. Burghen, J. R. Givens, and A. E. Kitabchi, "Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease, " Journal of Clinical Endocrinology and Metabolism, vol. 50, no. 1, pp. 113-116, 1980.
13. A. Dunaif, "Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis, " Endocrine Reviews, vol. 18, no. 6, pp. 774-800, 1997.
14. A. Dunaif, "Polycystic ovary syndrome and obesity, " in Obesity, P. Bjorntorp and B. N. Brodoff, Eds., pp. 594-605, J. B. Lippincott & Co., Philadelphia, Pa, USA, 1992.
15. G. Dona, C. Sabbadin, C. Fiore et al., "Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome, " European Journal of Endocrinology, vol. 166, no. 4, pp. 703-710, 2012.
16. B. Yildirim, N. Sabir, and B.Kaleli, "Relation of intra-Abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome, " Fertility and Sterility, vol. 79, no. 6, pp. 1358-1364, 2003.
17. D. A. Ehrmann, J. Sturis, M. M. Byrne, T. Karrison, R. L. Rosenfield, and K. S. Polonsky, "Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetesmellitus, " Journal of Clinical Investigation, vol. 96, no. 1, pp. 520-527, 1995.
18. Z. T. Bloomgarden, "Second world congress on the insulin resistance syndrome, " Diabetes Care, vol. 28, no. 7, pp. 1821-1830, 2005.
19. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adult (adult treatment panel III), " JAMA, vol. 285, pp. 2486-2497, 2001.
20. T. Apridonidze, P. A. Essah, M. J. Iuorno, and J. E. Nestler, "Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome, " Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 4, pp. 1929-1935, 2005.
21. A.D. Coviello, R. S. Legro, and A.Dunaif, "Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance, " Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 492-497, 2006.
22. S. Cook, M.Weitzman, P. Auinger, M.Nguyen, andW. H. Dietz, "Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994, " Archives of Pediatrics and Adolescent Medicine, vol. 157, no. 8, pp. 821-827, 2003.
23. S. D. De Ferranti, K. Gauvreau, D. S. Ludwig, E. J. Neufeld, J. W. Newburger, and N. Rifai, "Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey, " Circulation, vol. 110, no. 16, pp. 2494-2497, 2004.
24. S.Genuth, K. G. Alberti, P. Bennett et al., "Follow-up report on the diagnosis of diabetes mellitus, " Diabetes Care, vol. 26, no. 11, pp. 3160-3167, 2003.
25. D. A. Ehrmann, M. K. Cavaghan, R. B. Barnes, J. Imperial, and R. L. Rosenfield, "Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome, " Diabetes Care, vol. 22, no. 1, pp. 141-146, 1999.
26. M. J. Graf, C. J. Richards, V. Brown, L.Meissner, and A. Dunaif, "The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles inwomen, " Clinical Endocrinology, vol. 33, no. 1, pp. 119-131, 1990.
27. A. Dresner, D. Laurent, M. Marcucci et al., "Effects of free fatty acids on glucose transport and IRS-1-Associated phosphatidylinositol 3-kinase activity, " Journal of Clinical Investigation, vol. 103, no. 2, pp. 253-259, 1999.
28. J. M. Dekker, C. Girman, T. Rhodes et al., "Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study, " Circulation, vol. 112, no. 5, pp. 666-673, 2005.
29. A. Dunaif, K. R. Segal, D. R. Shelley, G. Green, A. Dobrjansky, and T. Licholai, "Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome, " Diabetes, vol. 41, no. 10, pp. 1257-1266, 1992.
30. A. Dunaif, J. Xia, C.-B. Book, E. Schenker, and Z. Tang, "Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: A potential mechanism for insulin resistance in the polycystic ovary syndrome, " The Journal of Clinical Investigation, vol. 96, no. 2, pp. 801-810, 1995.
31. S. A. Arslanian, V. D. Lewy, and K. Danadian, "Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and-cell dysfunction and risk of cardiovascular disease, " Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 1, pp. 66-71, 2001.
32. V.D. Lewy, K. Danadian, S. F.Witchel, and S. Arslanian, "Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome, " Journal of Pediatrics, vol. 138, no. 1, pp. 38-44, 2001.
33. F. Gonźalez, N. S. Rote, J. Minium, and J. P. Kirwan, "Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome, " Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 336-340, 2006.
34. A. N. Schüring, N. Schulte, B. Sonntag, and L. Kiesel, "Androgens and insulin-Two key players in polycystic ovary syndrome: recent concepts in the pathophysiology and genetics of polycystic ovary syndrome, " Gynakologisch-Geburtshilfliche Rundschau, vol. 48, no. 1, pp. 9-15, 2008.
35. R. J. Norman and A. M. Clark, Lifestyle Factors in the Etiology and Management of Polycystic Ovary Syndrome, Cambridge University Press, Cambridge, UK, 2000.
36. R. S. Legro, S. A. Arslanian, D. A. Ehrmann et al., "Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline, " Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 12, pp. 4565-4592, 2013.
37. J. Larner, L. C. Huang, G. Tang et al., "Insulin mediators: structure and formation, " Cold Spring Harbor Symposia on Quantitative Biology, vol. 53, no. 2, pp. 965-971, 1988.
38. J. E. Nestler, D. J. Jakubowicz, P. Reamer, R. D. Gunn, and G. Allan, "Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome, " The New England Journal of Medicine, vol. 340, no. 17, pp. 1314-1320, 1999.
39. T. T. Y. Chiu, M. S. Rogers, E. L. K. Law, C. M. Briton-Jones, L. P. Cheung, and C. J. Haines, "Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality, " Human Reproduction, vol. 17, no. 6, pp. 1591-1596, 2002.
40. W. H. Daughaday, J. Larner, and C. Hartnett, "The synthesis of inositol in the immature rat and chick embryo, " The Journal of Biological Chemistry, vol. 212, no. 2, pp. 869-875, 1955.
41. G. Di Paolo and P. De Camilli, "Phosphoinositides in cell regulation and membrane dynamics, " Nature, vol. 443, no. 7112, pp. 651-657, 2006.
42. J. Larner, "D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance, " International Journal of Experimental Diabetes Research, vol. 3, no. 1, pp. 47-60, 2002.
43. K. E. Barrett, S.M. Barman, S. Boitano, andH. Brook, "Chapter 2: overview of cellular physiology in medical physiology, " in Ganongs Review of Medical Physiology, K. E. Barrett, S. M. Barman, S. Boitano, and H. Brooks, Eds., p. 24e, 2012.
44. P. T. Goud, A. P. Goug, L. Leybaert et al., "Inositol 1, 4, 5-Trisphosphate receptor function in human oocytes: calcium responses and oocyte activation-related phenomena induced by photolytic release of InsP3 are blocked by a specific antibody to the type I receptor, " Molecular Human Reproduction, vol. 8, no. 10, pp. 912-918, 2002.
45. M. G. Myers and M. F. White, "The new elements of insulin signaling. Insulin receptor substrate-1 and protein with SH2 domains, " Diabetes, vol. 42, pp. 643-650, 1993.
46. J. Larner, G. Romero, A. S. Kennington et al., "Duality in the mechanism of action of insulin, " Advances in Second Messenger and Phosphoprotein Research, vol. 24, pp. 290-294, 1990.
47. J. Larner, L. C. Huang, C. F. W. Schwartz et al., "Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphatase contains galactosamine and D-chiroinositol, " Biochemical and Biophysical Research Communications, vol. 151, no. 3, pp. 1416-1426, 1988.
48. D. E. Misek and A. R. Saltier, "An inositol phosphate glycan derived from a Trypanosome brucei glycosylphosphatidylinositol mimics some of the metabolic actions of insulin, " The Journal of Biological Chemistry, vol. 267, pp. 16266-16273, 1992.
49. J. Larner, J. D. Price, D. Heimark et al., "Isolation, structure, synthesis, and bioactivity of a novel putative insulinmediator: A galactosamine chiro-inositol pseudo-disaccharideMn2+ chelate with insulin-like activity, " Journal of Medicinal Chemistry, vol. 46, no. 15, pp. 3283-3291, 2003.
50. J. E. Nestler, D. J. Jakubowicz, A. F. De Vargas, C. Brik, N. Quintero, and F. Medina, "Insulin stimulates testosterone biosynthesis by human thecal cells fromwomen with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system, " Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 6, pp. 2001-2005, 1998.
51. J. Larner, D. L. Brautigan, andM.O.Thorner, "D-chiro-inositol glycans in insulin signaling and insulin resistance, " Molecular Medicine, vol. 16, no. 11-12, pp. 543-551, 2010.
52. I. Asplin, G. Galasko, and J. Larner, "Chiro-inositol deficiency and insulin resistance: A comparison of the chiro-inositol-And the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, andmuscle of control and type II diabetic subjects, " Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 13, pp. 5924-5928, 1993.
53. J. Larner and J. W. Craig, "Urinary myo-inositol-To-chiroinositol ratios and insulin resistance, " Diabetes Care, vol. 19, no. 1, pp. 76-78, 1996.
54. J.-P. Baillargeon, E. Diamanti-Kandarakis, R. E. Ostlund Jr., T. Apridonidze, M. J. Iuorno, and J. E. Nestler, "Altered D-chiroinositol urinary clearance in women with polycystic ovary syndrome, " Diabetes Care, vol. 29, no. 2, pp. 300-305, 2006.
55. Y. Pak, Y. Hong, S. Kim, T. Piccariello, R. V. Farese, and J. Larner, "In vivo chiro-inositol metabolism in the rat: A defect in chiro-inositol synthesis from myo-inositol and an increased incorporation of chiro-[3H] inositol into phospholipid in the GOTO-Kakizaki (G.K.) Rat, " Molecules and Cells, vol. 8, no. 3, pp. 301-309, 1998.
56. H. Teede, A. Deeks, and L. Moran, "Polycystic ovary syndrome a complex condition with psychological, reproductive and metabolic manifestations that impacts on heath across the lifespan, " BMC Medicine, vol. 8, article 41, 2010.
57. T. T. Y. Chiu, M. S. Rogers, C. Briston-Jones, and C. Haines, "Effects of myo-inositol in the in-vitro maturation and the subsequent development of mouse oocyte, " Human Reproduction, vol. 18, no. 2, pp. 408-416, 2003.
58. J. Carroll, K. T. Jones, and D. G. Whittingham, "Ca2+ release and the development ofCa2+ releasemechanisms during oocyte maturation: A prelude to fertilization, " Reviews of Reproduction, vol. 1, no. 3, pp. 137-143, 1996.
59. E. Papaleo, V. Unfer, J. P. Baillargeon, and T. T. Chiu, "Contribution of myo-inositol to reproduction, " European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 147, no. 2, pp. 120-123, 2009.
60. M. J. Berridge and R. F. Irvine, "Inositol phosphates and cell signalling, " Nature, vol. 341, no. 6239, pp. 197-205, 1989.
61. G. Carlomagno, V. Unfer, and S. Roseff, "The D-chiro-inositol paradox in the ovary, " Fertility and Sterility, vol. 95, no. 8, pp. 2515-2516, 2011.
62. R. Isabella and E. Raffone, "Does ovary need D-chiro-inositol?" Journal of Ovarian Research, vol. 5, article 14, 2012.
63. F. Facchinetti, M. Bizzarri, S. Benvenga et al., "Results from the International Consensus Conference on Myo-inositol and dchiro-inositol in obstetrics and gynecology: The link between metabolic syndrome and PCOS, " European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 195, pp. 72-76, 2015.
64. A. S. Lagana, L. Barbaro, and A. Pizzo, "Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol, " Archives of Gynecology and Obstetrics, vol. 291, no. 5, pp. 1181-1186, 2015.
65. A. Pizzo, A. S. Lagana, and L. Barbaro, "Comparison between effects ofmyo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS, " Gynecological Endocrinology, vol. 30, no. 3, pp. 205-208, 2014.
66. A. D. Genazzani, C. Lanzoni, F. Ricchieri, and V. M. Jasonni, "Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome, " Gynecological Endocrinology, vol. 24, no. 3, pp. 139-144, 2008.
67. A. D. Genazzani, C. Battaglia, B. Malavasi, C. Strucchi, F. Tortolani, and O. Gamba, "Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome, " Fertility and Sterility, vol. 81, no. 1, pp. 114-119, 2004.
68. S. Gerli, M.Mignosa, and G. C. Di Renzo, "Effects of inositol on ovarian function and metabolic factors in women with PCOS: A randomized double blind placebo-controlled trial, " European Review for Medical and Pharmacological Sciences, vol. 7, no. 6, pp. 151-159, 2003.
69. M. Nordio and E. Proietti, "The combined therapy with myoinositol and D-Chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared tomyo-inositol supplementation alone, " European Review for Medical and Pharmacological Sciences, vol. 16, no. 5, pp. 575-581, 2012.
70. M. Minozzi, M. Nordio, and R. Pajalich, "The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients, " European Review for Medical and Pharmacological Sciences, vol. 17, no. 4, pp. 537-540, 2013.
71. C. Paul, A. S. Lagana, P. Maniglio, O. Triolo, and D. M. Brady, "Inositols and other nutraceuticals synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-The-Art and future perspectives, " Gynecological Endocrinology, vol. 32, no. 6, pp. 431-438, 2016.